Alvotech announced that the FDA has accepted its Biologics License Application (BLA) for AVT16, a proposed interchangeable biosimilar to Entyvio (vedolizumab) lyophilized vial. The company also released its unaudited condensed consolidated interim financial statements for the first three months of 2026.
